The effect of neoadjuvant chemotherapy on the prognosis of resectable gastric neuroendocrine carcinoma
10.3760/cma.j.cn113855-20210704-00408
- VernacularTitle:新辅助化疗对可切除胃神经内分泌癌预后的影响
- Author:
Kelei HUA
1
;
Yingkun REN
;
Mingke HUO
;
Zhichuang DONG
Author Information
1. 郑州大学附属肿瘤医院 河南省肿瘤医院普外科 450008
- Keywords:
Cancer, Neuroendocrine;
Chemotherapy, Adjuvant;
Stomach neoplasms;
Prognosis
- From:
Chinese Journal of General Surgery
2022;37(3):201-206
- CountryChina
- Language:Chinese
-
Abstract:
Objective:To investigate the effect of neoadjuvant chemotherapy on the prognosis of gastric neuroendocrine cancer.Methods:This study included 102 patients with gastric neuroendocrine cancer, the disease-free survival rate (DFS) and overall survival rate (OS) were compared between two groups according whether they were given neoadjuvant chemotherapy before radical resection.Results:Ninteen of the 102 patients received neoadjuvant chemotherapy combined with surgery, while the other 83 patients received upfront surgery . The 1-year survival rate of the direct operation group and the NAC group was 83.0% and 51.8%, respectively, and the 3-year survival rate was 63.0% and 33.3%, respectively ( χ2=9.182, P=0.002). The 1-year disease-free survival rate was 80.4% and 38.5%, respectively, and the 3-year disease-free survival rate was 59.8% and 25.7%, respectively ( χ2=11.142, P=0.001). Subgroup analysis showed that the difference between the two groups was mainly significant between MANEC patients ( χ2=10.742, P=0.001). Multivariate analysis showed that neoadjuvant therapy was an independent risk factor affecting the overall survival rate (all P<0.05). Univariate analysis shows that only adjuvant chemotherapy is the risk factor affecting disease-free survival ( P<0.05). When the neoadjuvant chemotherapy and the direct surgery were matched 1∶1, the OS and DFS of the direct surgery group were better than those of the NAC patients ( χ2=4.014, 3.954; P=0.045, 0.047). Conclusion:Neoadjuvant chemotherapy failed to improve the prognosis of patients with gastric neuroendocrine cancer/MANEC.
